Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.62)
# 232
Out of 5,014 analysts
47
Total ratings
61.22%
Success rate
29.52%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $37.48 | +70.76% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $23.78 | +42.98% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $8.57 | +63.36% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.15 | +312.70% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.99 | +37.67% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $6.64 | +65.66% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $2.28 | +31.58% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $3.00 | +133.33% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $11.82 | +43.82% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $19.66 | +42.42% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $18.25 | +113.70% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.59 | +404.73% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.46 | +100.76% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.28 | +40.19% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.54 | +83.49% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.60 | +51.52% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $14.00 | +64.29% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.72 | +67.69% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $37.48
Upside: +70.76%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $23.78
Upside: +42.98%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $8.57
Upside: +63.36%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.15
Upside: +312.70%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.99
Upside: +37.67%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $6.64
Upside: +65.66%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $2.28
Upside: +31.58%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $3.00
Upside: +133.33%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $11.82
Upside: +43.82%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $19.66
Upside: +42.42%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.25
Upside: +113.70%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $1.59
Upside: +404.73%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.46
Upside: +100.76%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.28
Upside: +40.19%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.54
Upside: +83.49%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $6.60
Upside: +51.52%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $14.00
Upside: +64.29%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.72
Upside: +67.69%